Abstract
Background
Orolingual angioedema can occur during thrombolysis with alteplase in stroke patients. However, data about its frequency, severity and the significance of concurrent use of angiotensin–converting–enzyme inhibitors (ACEi) are sparse.
Objective
(1), to alert to the potentially life–threatening complication of orolingual angioedema. (2), to present CT–scans of the tongue which exclude lingual hematoma. (3), to estimate the frequency of orolingual angioedema. (4), to evaluate the risk associated with the concurrent use of ACEi.
Methods
Single center, databank–based observational study on 120 consecutive patients with i. v. alteplase for acute stroke. Meta–analysis of all stroke studies on alteplase–associated angioedema, which provided detailed information about the use of ACEinhibitors. Across studies, the Peto odds ratio of orolingual angioedema for "concurrent use of ACEi" was calculated.
Results
Orolingual angioedema occurred in 2 of 120 patients (1.7%, 95% CI 0.2–5.9 %).Angioedema was mild in one, but rapidly progressive in another patient. Impending asphyxia prompted immediate intubation. CT showed orolingual swelling but no bleeding. One of 19 (5%) patients taking ACEi had orolingual angioedema, compared to 1 of 101 (1%) patients without ACEi. Medline search identified one further study about the occurrence of alteplase–associated angioedema in stroke patients stratified to the use of ACEi. Peto odds ratio of 37 (95 % CI 8–171) indicated an increased risk of alteplasetriggered angioedema for patients with ACEi (p <0.001).
Conclusion
Orolingual angioedema is a potentially life–threatening complication of alteplase treatment in stroke patients, especially in those with ACEi. Orolingual hematoma as differential diagnosis can be excluded by CT–scan.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Campos MM, Calixto JB (2000) Neurokinin mediation of edema and inflammation. Neuropeptides 34:314–322
Canadian Pharmacists Association (1999) In: Gillis CM, Welbanks L, Bergeron D, Cormier–Boyd M, Hachborn F, Jovaisas B, et al. (eds). Compendium of pharmaceuticals and specialties. 34th ed. Ottawa, Canada: Canadian Pharmacists Association, pp 31–34
Hill MD, Lye T, Moss H, Barber PA, Demchuk AM, Newcommon NJ, Green TL, Kenney C, Cole–Haskayne A, Buchan AM (2003) Hemi–orolingual angioedema and ACE inhibition after alteplase treatment of stroke. Neurology 60:1525–1527
Molinaro G, Gervais N, Adam A (2002) Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment: an in vitro experimental approach. Stroke 33:1712–1716
Pancioli A, Brott T, Donaldson V, Miller R (1997) Asymmetric angioneurotic edema associated with thrombolysis for acute stroke. Ann Emerg Med 30(2):227–229
Rudolf J, Grond M, Schmulling S, Neveling M, Heiss W (2000) Orolingual angioneurotic edema following therapy of acute ischemic stroke with alteplase. Neurology 55:599–600
Shaps HJ, Snyder GE, Sama AE, Rudolph GS (2001) Airway compromise secondary to lingual hematoma complicating administration of tissue plasminogen activator for acute ischemic stroke. Ann Emerg Med 38:447–449
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Engelter, S.T., Fluri, F., Buitrago–Téllez, C. et al. Life–threatening orolingual angioedema during thrombolysis in acute ischemic stroke. J Neurol 252, 1167–1170 (2005). https://doi.org/10.1007/s00415-005-0789-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-005-0789-9